Keyphrases
Global HIV
100%
Treatment Trials
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Antiretroviral Therapy
100%
Strategic Timing
100%
Transmitted Drug Resistance
100%
Australia
37%
Resistance Test
37%
Europe
25%
Basal Resistance
25%
Genotypic Resistance Testing
25%
Africa
12%
Standard of Care
12%
Protease
12%
South America
12%
Spain
12%
France
12%
Asia
12%
Protease Inhibitors
12%
World Health Organization
12%
Testing Rates
12%
Nave
12%
Reverse Transcriptase
12%
Prevalence Rate
12%
Nucleoside Reverse Transcriptase Inhibitors
12%
Resistance mutations
12%
K103N
12%
Participant Characteristics
12%
Resource-rich
12%
Trial Participants
12%
Transmitted Drug Resistance mutations
12%
Developed Area
12%
Resistance Prevalence
12%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
12%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Drug Resistance
100%
Prevalence
44%
Resistance Mutation
22%
Reverse-Transcriptase Inhibitor
11%
Population Research
11%
Study Participant
11%
Proteinase
11%
Proteinase Inhibitor
11%
Nonnucleoside Reverse Transcriptase Inhibitor
11%
RNA Directed DNA Polymerase
11%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus 1
100%
Drug Resistance
100%
Prevalence
44%
Reverse Transcriptase
33%
Protease Inhibitor
11%
Population Research
11%
Nucleoside
11%
Protease
11%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Drug Resistance
100%
Prevalence
44%
Population Study
11%
Proteinase
11%
RNA Directed DNA Polymerase
11%
Proteinase Inhibitor
11%
RNA Directed DNA Polymerase Inhibitor
11%
Nonnucleoside Reverse Transcriptase Inhibitor
11%
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Drug Resistance
100%
Prevalence
44%
Reverse Transcriptase
33%
Population Research
11%